排序方式: 共有3条查询结果,搜索用时 386 毫秒
1
1.
Over the last decades, the evaluation of potential surrogate endpoints in clinical trials has steadily been growing in importance,
not only thanks to the availability of ever more potential markers and surrogate endpoints, also because more methodological
development has become available. While early work has been devoted, to a large extent, to Gaussian, binary, and longitudinal
endpoints, the case of time-to-event endpoints is in need of careful scrutiny as well, owing to the strong presence of such
endpoints in oncology and beyond. While work had been done in the past, it was often cumbersome to use such tools in practice,
because of the need for fitting copula or frailty models that were further embedded in a hierarchical or two-stage modeling
approach. In this paper, we present a methodologically elegant and easy-to-use approach based on information theory. We resolve
essential issues, including the quantification of “surrogacy” based on such an approach. Our results are put to the test in
a simulation study and are applied to data from clinical trials in oncology. The methodology has been implemented in R. 相似文献
2.
Theory and Decision - The risky investment game of Gneezy and Potters (Q J Econ 112(2):631–645, 1997) has been proposed as a simple tool to measure risk aversion in applied settings,... 相似文献
3.
Geert Molenberghs Tomasz Burzykowski Ariel Alonso Pryseley Assam Abel Tilahun Marc Buyse 《Journal of statistical planning and inference》2008
For a number of reasons, surrogate endpoints are considered instead of the so-called true endpoint in clinical studies, especially when such endpoints can be measured earlier, and/or with less burden for patient and experimenter. Surrogate endpoints may occur more frequently than their standard counterparts. For these reasons, it is not surprising that the use of surrogate endpoints in clinical practice is increasing. 相似文献
1